相关临床试验
7
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1821
进行中（未招募）
1
14.3%
已完成
4
57.1%
尚未招募
1
14.3%
Unknown
1
14.3%
暂无批准数据
- Heriot-Watt University has secured over £475,000 in funding from Scottish Enterprise and the Medical Research Council to advance clinical trials of a groundbreaking vibroacoustic sensor technology for eczema diagnosis and treatment. - The innovative device emits small vibrations onto the skin surface to measure tissue stiffness and fluid content changes, providing objective measurements that could replace subjective visual assessments in dermatological care. - The technology addresses critical healthcare disparities by working equally well on all skin tones, potentially eliminating biases in visual assessments that are particularly unreliable for patients with darker skin. - Clinical trials will begin testing the sensor on patients with moderate eczema undergoing third or fourth-line treatments, with the goal of enabling faster, data-driven treatment decisions and reducing years of patient suffering.
- A new ultrasound imaging technique demonstrates a 94% sensitivity rate in detecting prostate tumors in initial clinical trials, offering a potentially more reliable screening method. - The super-resolution ultrasound imaging (SRUI) technology uses microbubbles and existing ultrasound equipment, providing up to a 20-fold increase in resolution compared to MRI. - Developed by Less Grey Imaging, the technique aims to streamline workflows, reduce NHS costs, and improve patient outcomes through earlier and more accurate diagnoses. - The new imaging approach could reduce the number of men sent for unnecessary MRIs and risky biopsies, while also improving treatment outcomes through earlier detection.
